Table 1.
Long COVID-19 outpatient demographics and clinical data
| Initial infection variable | Outpatients (n = 23) |
|---|---|
| Age (yrs), median (IQR) | 61.0 (19.0) |
| Male sex, no. (%) | 13 (56.5) |
| Diagnostic test: PCR, serology, no. (%) | 23 (100.0) |
| Vaccination status at infection, no. (%) | 2 (8.7) |
| Hospitalization, no. (%) | |
| Ward | 7 (30.4) |
| ICU | 1 (4.3) |
| Comorbidities, no. (%) | |
| Diabetes | 6 (26.1) |
| Hypertension | 8 (34.8) |
| Coronary artery/heart disease | 2 (8.7) |
| Chronic/congestive heart failure | 0 (0.0) |
| Chronic kidney disease | 0 (0.0) |
| Cancer | 1 (4.3) |
| COPD | 0 (0.0) |
| Asthma | 4 (17.4) |
| Presenting symptoms at infection, no. (%) | |
| Fever | 16 (69.6) |
| Cough | 18 (78.3) |
| Anosmia/ageusia | 14 (60.9) |
| Pharyngitis | 9 (39.1) |
| Headache | 14 (60.9) |
| Confusion/memory | 2 (8.7) |
| Myalgias | 13 (56.5) |
| Dyspnea | 16 (69.6) |
| Chest pain | 8 (34.8) |
| Nausea/vomiting/diarrhea | 12 (52.2) |
| Interventions at infection, no. (%) | |
| Steroids | 7 (30.4) |
| Remdesivir | 1 (4.3) |
| Tocilizumab | 1 (4.3) |
| Long-COVID clinic variables | |
| Follow up, days from infection onset, median (IQR) | 98.5 (47.5) |
| Lingering symptoms at follow up, no. (%) | |
| Respiratory | 16 (69.6) |
| Cardiovascular | 6 (26.1) |
| Neurology | 9 (39.1) |
| Musculoskeletal | 1 (4.3) |
| Gastro-Intestinal | 3 (13.0) |
| Psychiatric | 1 (4.3) |
| Cutaneous | 0 (0.0) |
| Balance | 0 (0.0) |
| Chest pain | 4 (17.4) |
| Concentration | 1 (4.3) |
| Cough | 2 (8.7) |
| Dyspnea | 16 (69.6) |
| Fatigue | 11 (47.8) |
| Headache | 2 (8.7) |
| Low mood | 1 (4.3) |
| Anxiety | 1 (4.3) |
| Memory | 7 (30.4) |
| Nausea | 1 (4.3) |
| Palpitations | 1 (4.3) |
| Paresthesia | 1 (4.3) |
| Smell/taste | 2 (8.7) |
| Word finding | 2 (8.7) |
| Non-specific | 11 (47.8) |
| Laboratories at follow up, median (IQR) | |
| White blood cell count | 7.1 (2.0) |
| Neutrophils | 4.5 (1.6) |
| Lymphocytes | 2.0 (0.6) |
| Hemoglobin | 140.0 (22.5) |
| Platelets | 230.0 (59.5) |
| C-Reactive Protein (CRP) | 1.8 (3.5) |
| Ferritin | 86.5 (133.8) |
| Lactate dehydrogenase (LDH) | 201.0 (37.0) |
| Alanine aminotransferase (ALT) | 20.0 (10.5) |
| Interventions at follow up, no. (%) | |
| Pulmicort | 1 (4.3) |
| Anticoagulant | 1 (4.3) |
| Symbicort | 10 (43.5) |
| Ventolin | 3 (13.0) |
| Lasix | 1 (4.3) |
| Nasal spray | 2 (8.7) |
| Oxygen | 2 (8.7) |
| Physiotherapy | 5 (21.7) |
| None | 8 (34.8) |